Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP101G + ASP2802 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP101G | ASP 101G|ASP-101G|MA-20|MA20 | Limited information is currently available on ASP101G (Jul 2024). | ||
| ASP2802 | ASP-2802|ASP 2802 | ASP2802 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting a modified form of NKG2D, which upon activation by the CD20-targeted bispecific adaptor ASP101G potentially induce killing of tumor cells expressing CD20 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Terminated | AUS | 0 |